Objective: To assess the disease response and patient survival outcomes for cancer patients treated with helical tomotherapy.
Study Design: Descriptive study. Place and Duration of the Study: The Tomotherapy Unit of Jinnah Postgraduate Medical Centre, Karachi, Pakistan, from October 2020 to August 2023.
Methodology: A retrospective analysis was conducted on the data of patients who underwent definitive radiation at Tomotherapy Centre. The evaluation of disease response utilised CT scans performed three months after completing radiotherapy, following RECIST criteria. Survival and disease-free status were determined through telephonic interviews with the patients.
Results: A total of 654 patients received treatment on Tomotherapy, of which, 143 underwent definitive Radiotherapy. The average age was 51 ± 16.8 years, with 85 (59.4%) males. The predominant area subjected to definitive radiation was the head and neck, accounting for 65 cases (45.5%), trailed by the gastrointestinal tract and pelvis with 52 (36.4%) and 26 (18.2%) cases, respectively. Response assessment revealed a complete response in 73 (52.14%) patients, partial response in 47 (33.5%), stable disease in 11 (7.85%), and progressive disease in 9 (6.4%). Currently, 108 (77%) patients are alive. Twenty-eight (20%) patients experienced local or distant disease development. Among them, 6 (4.3%) patients had local recurrence, and 22 (15.7%) developed metastatic disease.
Conclusion: Helical tomotherapy offers promising disease control and survival outcomes, making it a viable treatment modality for cancer patients in a lower middle-income country. These findings highlight the importance of careful patient selection and optimising resource utilisation for curative treatments to enhance cancer care in Pakistan.
Key Words: Radiotherapy, Tomotherapy, Radiotherapy technique, Multidisciplinary treatment, Peer-review practice.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.29271/jcpsp.2025.01.66 | DOI Listing |
J Cancer Surviv
January 2025
Leeds Institute of Medical Research at St James's, University of Leeds, Leeds, UK.
Purpose: Radiotherapy (RT) for oropharyngeal cancer (OPC) can lead to late toxicity. Fatigue is a known debilitating issue for many cancer survivors, yet prevalence and severity of long-term fatigue in patients treated for OPC is unknown.
Method: As part of a mixed-methods study, fatigue in OPC patients ≥ 2 years post RT + / - chemotherapy was evaluated.
Tumour 'bulk' has historically been considered an important prognostic marker and clinical tool to guide treatment in patients with lymphoma. However, its use and definitions in trial designs varies significantly and it is unclear how this has influenced the relevance of bulk in contemporary practice. This comprehensive literature review evaluated the definitions, applications and prognostic impact of bulk in phase 3 randomised trials in four major lymphoma subtypes.
View Article and Find Full Text PDFJ Coll Physicians Surg Pak
January 2025
Department of Radiation Oncology, CyberKnife and Tomotherapy Centre, Jinnah Postgraduate Medical Centre, Karachi, Pakistan.
Objective: To assess the disease response and patient survival outcomes for cancer patients treated with helical tomotherapy.
Study Design: Descriptive study. Place and Duration of the Study: The Tomotherapy Unit of Jinnah Postgraduate Medical Centre, Karachi, Pakistan, from October 2020 to August 2023.
Radiat Oncol
January 2025
Department of Radiation Oncology, Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Tianjin, 300060, China.
Background: Several studies have suggested that lung tissue heterogeneity is associated with overall survival (OS) in lung cancer. However, the quantitative relationship between the two remains unknown. The purpose of this study is to investigate the prognostic value of whole lung-based and tumor-based radiomics for OS in LA-NSCLC treated with definitive radiotherapy.
View Article and Find Full Text PDFDis Esophagus
January 2025
Department of Esophageal Surgery, National Cancer Center, Tokyo, Japan.
Definitive chemoradiotherapy (dCRT) is the standard treatment for unresectable (T4) esophageal squamous cell carcinoma (ESCC), but the prognosis is poor. Borderline resectable (T3br) ESCC has been discussed, but its clinical features and appropriate treatment are unclear. The effects of docetaxel plus cisplatin and 5-fluorouracil (DCF) therapy and subsequent surgery for potentially unresectable ESCC remain controversial.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!